ライフサイエンスコーパス: joint swelling

1 tage), thickness of the synovial lining, and joint swelling.

2 as highly effective at reversing established joint swelling.

3 pressive effect of CD44-specific antibody on joint swelling.

4 of CIA with PLP-LCL significantly suppressed joint swelling.

5 prinomastat were arthralgia, stiffness, and joint swelling.

6 s global assessment of disease activity, and joint swelling.

7 joint tenderness, despite improvement of the joint swelling.

8 The 7 ACR Core Data Set measures of 1) joint swelling, 2) joint tenderness, 3) physician global

9 derness, 56% versus 41% (P = 0.021), and for joint swelling, 54% versus 39% (P = 0.023); by Paulus cr

10 but that its deficiency resulted in earlier joint swelling and an inability to resolve arthritis as

11 tion of C3H IL-10(-/-) mice led to increased joint swelling and arthritis severity scores over those

12 rence of arthritis, as assessed by measuring joint swelling and by the gross-observation score, and a

13 ficantly reduced inflammation as assessed by joint swelling and clinical inflammation scores.

14 hronic erosive disease typified by disabling joint swelling and deformity (articular index = 8.17+/-0

15 inase (JNK) 1, but not JNK2, is critical for joint swelling and destruction in a serum transfer model

16 se of systemic SCW, virtually eliminated the joint swelling and destruction typically observed during

17 Efficacy in preventing joint swelling and destruction was determined clinically

18 mice interleukin (IL)-1 plays a key role in joint swelling and destruction, as suggested by the abil

19 Joint swelling and disability peaked at 2 weeks of infec

20 h B. burgdorferi developed higher degrees of joint swelling and higher anti-B. burgdorferi immunoglob

21 Arthritis was assessed by measurement of joint swelling and histology of joints collected at d 14

22 s by administration of PG-PS, causing tarsal joint swelling and histopathologic changes characteristi

23 erall severity of arthritis as determined by joint swelling and histopathology.

24 a, as measured by laser Doppler imaging, and joint swelling and hyperemic responses to recombinant hu

25 0 mg daily) resulted in modest inhibition of joint swelling and inhibition of radiographic progressio

26 Within a trial, joint swelling and joint tenderness or patient and physi

27 and inflammation was determined by measuring joint swelling and macrophage percentage area.

28 The effects of IL-1Ra on joint swelling and radiographic bone damage in patients

29 tor-alpha and interleukin-1 beta, abrogating joint swelling and reducing destruction of bone and cart

30 Joint swelling and serum levels of hyaluronan (HA) and s

31 contributes to the generation of early-onset joint swelling and suggests that arp expression has a ne

32 l synthetic PAR-2 agonist, induced prolonged joint swelling and synovial hyperemia.

33 n B. burgdorferi infection, showed increased joint swelling and synovial inflammation compared with n

34 eta-tryptase resulted in dose-dependent knee joint swelling and synovial vasodilatation in PAR-2(+/+)

35 s (patient and physician global assessments, joint swelling and tenderness counts, and global pain as

36 tient pain assessment than to changes in the joint swelling and tenderness counts.

37 Clinical outcomes evaluated included pain, joint swelling and tenderness, activities of daily livin

38 patient-centered) outcomes, such as pain and joint swelling and tenderness; and adverse effects of th

39 in rats was investigated to address whether joint swelling and the associated vascular dysfunction a

40 The maximum severity of joint swelling and the duration of Lyme arthritis after

41 In conclusion, the joint swelling and vascular dysfunction associated with

42 In both arthritis models clinical (joint swelling) and histologic indices of inflammatory a

43 s intraarticular accumulation of leukocytes, joint swelling, and bone erosion.

44 expression, pannus formation, bone erosion, joint swelling, and pain.

45 , swelling of MyD88(-/-) joints surpassed WT joint swelling, and resolution of joint inflammation was

46 s, as evidenced by significant reductions in joint swelling at wk 5, 6, and 7 postinfection, and in t

47 t in joint tenderness and 50% improvement in joint swelling, based on joint scores).

48 hibition of HDAC1 in CIA resulted in reduced joint swelling, cartilage and bone damage and lower tumo

49 The maximum severity of joint swelling correlated directly with the response to

50 ria (20% improvement in joint tenderness and joint swelling counts, and in 3 of 5 other measures: phy

51 monstrated significantly reduced tibiotarsal joint swelling during the first 6 weeks of infection com

52 tic-refractory arthritis, who had persistent joint swelling for a median duration of 10 months despit

53 although substitution of metacarpophalangeal joint swelling for erosion produced a higher RA prevalen

54 Serotype B-infected mice had greater joint swelling, functional disability, and leukocytic in

55 receptors displayed protective phenotypes in joint swelling, histologic changes in inflammation, and

56 CM-MSC treatment significantly reduced knee-joint swelling, histopathological signs of AIA, cartilag

57 ively prevents arthritis onset and abrogates joint swelling in established disease.

58 mg/kg of losartan substantially reduced knee joint swelling in rats with adjuvant monarthritis (> or

59 ody (versus control antibody) did not affect joint swelling in SCW-treated animals.

60 rthritis, Ifitm3(-/-) mice sustained greater joint swelling in the ipsilateral ankle at days 3 and 7

61 After i.v. PG-PS treatment joint swelling increased 2.1 +/- 0.3 mm in controls but

62 y indices (patient or physician assessment), joint swelling, joint pain or tenderness, erythrocyte se

63 e suggests that targeting PAR-2 helps reduce joint swelling observed in animal models of arthritis.

64 se, as assessed clinically by measurement of joint swelling on day 1 (P < 0.0001), day 2 (P < 0.01),

65 tor activator of NF-kappaB ligand, and block joint swelling, osteoclast recruitment, and osteolysis.

66 culoskeletal stiffness, cramps, weakness and joint swelling (P < .001), cataract surgery (P < .001),

67 nduced arthritis model in rats, 37 prevented joint swelling partially at 10 mg/kg.

68 ivity, erythrocyte sedimentation rate [ESR], joint swelling, radiographic changes, RA nodules, RA com

69 ations, and joint pain/tenderness scores and joint swelling scores in patients with peripheral articu

70 in 4 of 6 measures: joint tenderness scores, joint swelling scores, physician's and patient's global

71 idence interval [CI], 78%-90%), a history of joint swelling (sensitivity, 78%; 95% CI, 71%-85%), and

72 e, including a reduction in inflammation and joint swelling, suggesting that PPS is a promising candi

73 We previously reported that joint swelling, synovial thickening, and cartilage matri

74 ) mice exacerbated anti-collagen/LPS-induced joint swelling that was abolished by neutrophil depletio

75 ith antibiotic-responsive arthritis, in whom joint swelling usually resolved during a 1-month course

76 While COX-1/COX-2 inhibition reduced joint swelling, vascular dysfunction in AIA is independe

77 n-site AEs from days 1 to 5, and joint pain, joint swelling, vesicular lesions (blisters), and rashes

78 Joint swelling was measured and histologic analysis was

79 ion halted, but a significant improvement in joint swelling was observed within 2 days of treatment.

80 n, appeared early after immunization, before joint swelling was observed.

81 The severity of joint swelling was restored to wild-type levels in mice

82 Joint swelling was similarly attenuated by indomethacin

83 monoarthritis model of chronic inflammation, joint swelling was substantially inhibited in PAR-2-defi

84 T cells are essential for the development of joint swelling without any effect on virus replication a